A5.12.14 [5.12.14] (ATCC® HB-11553)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybri  / 

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody.
Genes Expressed
immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8)
Cellular Products
immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8)
Comments
Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 10(5) viable cells/ml. Do not allow the cell concentration to exceed 5 X 10(5) cells/ml.
Interval: Maintain cultures at a cell concentration between 3 X 10(4) and 4 X 10(5) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium described above supplemented with 5% (v/v) DMSO.
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG2a kappa
Name of Depositor Genentech, Inc.
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Basic Documentation
Other Documentation
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000